ARVINAS INC
For the period ended Dec 31, 2023. Filed Feb 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 27, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
None.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| ARVINAS, INC. | ||
| Date: February 27, 2024 | By: | /s/ David K. Loomis |
|---|---|---|
| David K. Loomis | ||
| Vice President and Chief Accounting Officer | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the registrant in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ John Houston, Ph.D. | President, Chief Executive Officer and Chairman of the Board of Directors | February 27, 2024 |
| John Houston, Ph.D. | (principal executive officer) | |
| /s/ Sean Cassidy | Chief Financial Officer and Treasurer | February 27, 2024 |
| Sean Cassidy | (principal financial officer) | |
| /s/ David K. Loomis | Vice President and Chief Accounting Officer | February 27, 2024 |
| David K. Loomis | (principal accounting officer) | |
| /s/ Sunil Agarwal, M.D. | Director | February 27, 2024 |
| Sunil Agarwal, M.D. | ||
| /s/ Linda Bain | Director | February 27, 2024 |
| Linda Bain | ||
| /s/ Everett Cunningham | Director | February 27, 2024 |
| Everett Cunningham | ||
| /s/ Wendy Dixon, Ph.D. | Director | February 27, 2024 |
| Wendy Dixon, Ph.D. | ||
| /s/ Edward Kennedy, Jr. | Director | February 27, 2024 |
| Edward Kennedy, Jr. | ||
| /s/ Briggs Morrison, M.D. | Director | February 27, 2024 |
| Briggs Morrison, M.D. | ||
| /s/ Leslie Norwalk, Esq. | Director | February 27, 2024 |
| Leslie Norwalk, Esq. | ||
| /s/ Laurie Smaldone Alsup, M.D. | Director | February 27, 2024 |
| Laurie Smaldone Alsup, M.D. | ||
| /s/ John Young | Director | February 27, 2024 |
| John Young | ||
Index to Consolidated Financial Statements
| Page | |
| Report of Independent Registered Public Accounting Firm (PCAOB ID No.34) | F-2 |
|---|---|
| Consolidated Balance Sheets | |
| December 31, 2023 and 2022 | F-4 |
| Consolidated Statements of Operations and Comprehensive Loss | |
| Years ended December 31, 2023, 2022 and 2021 | F-5 |
| Consolidated Statements of Changes in Stockholders’ Equity | |
| Years ended December 31, 2023, 2022 and 2021 | F-6 |
| Consolidated Statements of Cash Flows | |
| Years ended December 31, 2023, 2022 and 2021 | F-7 |
| Notes to Consolidated Financial Statements | F-8 |
F - 1
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.